Use and Spending on Antineoplastic Therapy for Medicare Beneficiaries With Cancer

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Medical Care

• Publication date

  2013-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/MLR.0b013e3182726cebPMID 23222498
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Projections of the cost of cancer care in the United States: 2010-2020.

  2011cited by this paper
• Impact of new drugs and biologics on colorectal cancer treatment and costs.

  2011cited by this paper
• Impact of new drugs and biologics on colorectal cancer treatment and costs.

  2011cited by this paper
• Cancer stage comparison between dual Medicare-Medicaid eligibles using Medicaid as a supplemental health insurance program and low-income nonduals.

  2011cited by this paper
• The value of specialty oncology drugs.

  2010cited by this paper
• Celebrating the New

  2008cited by this paper
• Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis.

  2008cited by this paper
• Evaluation of trends in the cost of initial cancer treatment.

  2008cited by this paper
• NCCN Task Force Report: Oral chemotherapy.

  2008cited by this paper
• Medicare Challenges and Solutions - reimbursement Issues in Treating the Patient with Colorectal Cancer

  2007cited by this paper
• Benefit design and specialty drug use.

  2006cited by this paper
• Anastrozole data show continued delay in relapse, but no clear survival advantage.

  2005cited by this paper
• The price tag on progress--chemotherapy for colorectal cancer.

  2004cited by this paper
• Derivation of Malignancy Status from ICD-9 Codes

  2003cited by this paper
• Reporting of Drug Expenditures in the MCBS

  2003cited by this paper
• A changing paradigm for cancer treatment: the advent of new oral chemotherapy agents.

  2003cited by this paper
• Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population

  2002cited by this paper
• The sensitivity of Medicare claims data for case ascertainment of six common cancers.

  1999cited by this paper
• Evolving role of oral chemotherapy for the treatment of patients with neoplasms.

  1998cited by this paper
• Tamoxifen in the treatment of breast cancer.

  1998cited by this paper
• Tamoxifen in the Treatment of Breast Cancer

  1998cited by this paper
• Medicare coverage for oncology services

  1998cited by this paper
• Tamoxifen in the treatment of breast cancer.

  1988cited by this paper

• Racial/ethnic disparities in measure calculations for Part D Star Ratings among Medicare beneficiaries with diabetes, hypertension, and/or hyperlipidemia.

  2020cites this paper
• Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries.

  2018cites this paper
• The Price Elasticity of Specialty Drug Use: Evidence from Cancer Patients in Medicare Part D

  2017cites this paper
• Did Medicare Part D reduce mortality?

  2017cites this paper
• Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.

  2017cites this paper
• Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma

  2016cites this paper
• Receipt of chemotherapy among medicare patients with cancer by type of supplemental insurance.

  2015cites this paper
• Hospitalization burden and survival among older glioblastoma patients.

  2014cites this paper
• Influence of Socioeconomic Status on Survival and Clinical Outcomes in Patients with Advanced Gastric Cancer after Chemotherapy

  2014cites this paper
• Use of and spending on supportive care medications among Medicare beneficiaries with cancer

  2014cites this paper